FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137070812> ?p ?o ?g. }

• W2137070812 endingPage "2284" @default.
• W2137070812 startingPage "2275" @default.
• W2137070812 abstract "This phase I study evaluated afatinib, an irreversible ErbB family blocker, plus paclitaxel in patients with advanced solid tumours likely to express human epidermal growth factor receptor (HER1/EGFR) or HER2.Oral afatinib was combined with intravenous paclitaxel (80mg/m(2); days 1, 8 and 15 every four weeks) starting at 20mg once daily and escalated to 40 and 50mg in successive cohorts of ⩾3 patients. The primary objective was to determine the maximum tolerated dose (MTD) of afatinib combined with paclitaxel. Secondary objectives included safety, pharmacokinetics and antitumour activity.Sixteen patients were treated. Dose-limiting toxicities with afatinib 50mg were fatigue and mucositis. The MTD was determined as afatinib 40mg with paclitaxel 80mg/m(2), which proved tolerable with repeated dosing. Frequent adverse events (AEs) included diarrhoea (94%), fatigue (81%), rash/acne (81%), decreased appetite (69%) and inflammation of mucosal membranes (69%); no grade 4 treatment-related AEs were observed. Five (31%) confirmed partial responses were observed in patients with non-small cell lung cancer (n=3), oesophageal cancer and cholangiocarcinoma; eight (50%) patients remained on study for ⩾6months. Pharmacokinetic parameters of afatinib and paclitaxel were similar for single administration or in combination.The MTD and recommended phase II dose of once-daily afatinib combined with paclitaxel 80mg/m(2) (days 1, 8 and 15 every four weeks) was 40mg. AEs at or below this dose were generally manageable with repeated dosing. No pharmacokinetic interactions were observed. This combination demonstrated promising antitumour activity.ClinicalTrials.gov, NCT00809133." @default.
• W2137070812 created "2016-06-24" @default.
• W2137070812 creator A5009812253 @default.
• W2137070812 creator A5011225110 @default.
• W2137070812 creator A5022418747 @default.
• W2137070812 creator A5030172446 @default.
• W2137070812 creator A5034748028 @default.
• W2137070812 creator A5056665938 @default.
• W2137070812 creator A5068129829 @default.
• W2137070812 creator A5070801716 @default.
• W2137070812 creator A5070907717 @default.
• W2137070812 creator A5072378199 @default.
• W2137070812 creator A5081939931 @default.
• W2137070812 creator A5084636017 @default.
• W2137070812 creator A5088144652 @default.
• W2137070812 date "2015-11-01" @default.
• W2137070812 modified "2023-09-27" @default.
• W2137070812 title "A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours" @default.
• W2137070812 cites W1947624718 @default.
• W2137070812 cites W1989931815 @default.
• W2137070812 cites W2000800064 @default.
• W2137070812 cites W2022392694 @default.
• W2137070812 cites W2063391304 @default.
• W2137070812 cites W2071539936 @default.
• W2137070812 cites W2073901381 @default.
• W2137070812 cites W2074819793 @default.
• W2137070812 cites W2096198395 @default.
• W2137070812 cites W2110835998 @default.
• W2137070812 cites W2114095518 @default.
• W2137070812 cites W2123528875 @default.
• W2137070812 cites W2125760261 @default.
• W2137070812 cites W2127101185 @default.
• W2137070812 cites W2130727852 @default.
• W2137070812 cites W2132540363 @default.
• W2137070812 cites W2132870547 @default.
• W2137070812 cites W2138851777 @default.
• W2137070812 cites W2152905269 @default.
• W2137070812 cites W2154094988 @default.
• W2137070812 cites W2160336497 @default.
• W2137070812 cites W2162394887 @default.
• W2137070812 cites W2162724777 @default.
• W2137070812 cites W2166070477 @default.
• W2137070812 cites W2171139285 @default.
• W2137070812 doi "https://doi.org/10.1016/j.ejca.2015.07.041" @default.
• W2137070812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26296295" @default.
• W2137070812 hasPublicationYear "2015" @default.
• W2137070812 type Work @default.
• W2137070812 sameAs 2137070812 @default.
• W2137070812 citedByCount "23" @default.
• W2137070812 countsByYear W21370708122015 @default.
• W2137070812 countsByYear W21370708122016 @default.
• W2137070812 countsByYear W21370708122017 @default.
• W2137070812 countsByYear W21370708122018 @default.
• W2137070812 countsByYear W21370708122019 @default.
• W2137070812 countsByYear W21370708122020 @default.
• W2137070812 countsByYear W21370708122021 @default.
• W2137070812 countsByYear W21370708122022 @default.
• W2137070812 countsByYear W21370708122023 @default.
• W2137070812 crossrefType "journal-article" @default.
• W2137070812 hasAuthorship W2137070812A5009812253 @default.
• W2137070812 hasAuthorship W2137070812A5011225110 @default.
• W2137070812 hasAuthorship W2137070812A5022418747 @default.
• W2137070812 hasAuthorship W2137070812A5030172446 @default.
• W2137070812 hasAuthorship W2137070812A5034748028 @default.
• W2137070812 hasAuthorship W2137070812A5056665938 @default.
• W2137070812 hasAuthorship W2137070812A5068129829 @default.
• W2137070812 hasAuthorship W2137070812A5070801716 @default.
• W2137070812 hasAuthorship W2137070812A5070907717 @default.
• W2137070812 hasAuthorship W2137070812A5072378199 @default.
• W2137070812 hasAuthorship W2137070812A5081939931 @default.
• W2137070812 hasAuthorship W2137070812A5084636017 @default.
• W2137070812 hasAuthorship W2137070812A5088144652 @default.
• W2137070812 hasBestOaLocation W21370708122 @default.
• W2137070812 hasConcept C112705442 @default.
• W2137070812 hasConcept C121608353 @default.
• W2137070812 hasConcept C126322002 @default.
• W2137070812 hasConcept C143998085 @default.
• W2137070812 hasConcept C197934379 @default.
• W2137070812 hasConcept C2776694085 @default.
• W2137070812 hasConcept C2777292972 @default.
• W2137070812 hasConcept C2778496288 @default.
• W2137070812 hasConcept C2778570526 @default.
• W2137070812 hasConcept C2779438470 @default.
• W2137070812 hasConcept C2780580887 @default.
• W2137070812 hasConcept C2780586478 @default.
• W2137070812 hasConcept C71924100 @default.
• W2137070812 hasConcept C90924648 @default.
• W2137070812 hasConcept C98274493 @default.
• W2137070812 hasConceptScore W2137070812C112705442 @default.
• W2137070812 hasConceptScore W2137070812C121608353 @default.
• W2137070812 hasConceptScore W2137070812C126322002 @default.
• W2137070812 hasConceptScore W2137070812C143998085 @default.
• W2137070812 hasConceptScore W2137070812C197934379 @default.
• W2137070812 hasConceptScore W2137070812C2776694085 @default.
• W2137070812 hasConceptScore W2137070812C2777292972 @default.
• W2137070812 hasConceptScore W2137070812C2778496288 @default.
• W2137070812 hasConceptScore W2137070812C2778570526 @default.
• W2137070812 hasConceptScore W2137070812C2779438470 @default.

• next